! **, ( -#. /) )* + ( ' ) "# $% 0 1% : 65! : 62 / : 62 7! 8 92"
|
|
- Curtis Jones
- 8 years ago
- Views:
Transcription
1 (%*) %&( %&'!"#$! **(,-#./) )* +*(') "# $%!" #$ % * $ '(' & ** 01%.!" # $ % & :23 / % 012.-% ()*. /,- ()* +!".7 % 612 # $ % &? %*:2 ; % % </ =; > %& # & 6,7,/ =. % & 89 :65!! Hb 1 7D, = * 6*,& 3,/ 6*,.- 7F,? < #2!/ TG,.LDL E%* QRS T2 >, S / < D 3, (K?/8O 2 %NN 2 1 %9H) K /H Hb 1 G; :62/ %N/9 3, % Hb 1 X. 2, Hb 1 K U/U8 ()* 6+ (p=u/uuv)? 2 1 %9H) ()* Y 9/8N EF 6* 3 / %&. (432 %N) K U/8? 2, Y / 3,.(P< U/UUUH) 3,/ 6* & ( %8N / 6* (Y ()* (kg O/HV 2 /H L %9H) #!/ 8/UV /% 6* 2 / %&./ D (/ (Y /9 2 /?O L %9H).S %=,!2 LDL E#2!/ 4T2 Z[.S %= 432 / / D T2-2, 6+ Hb 1 (/ K N/V \] 3 / *^ :627! 892".-% 612 # $ % & 5_ %F&/ > 3. < 6 &/ %8N
2 234 /...+#, -%.% /!" )*% 65!! 23 & : X- =; & 8U gy -, QRS2 %7 8U = / % NU &/ Y! Y. %N 2f < Hb 1-2f < cr / %& E- %7! Y : / % >/f [ ; / %& /H -d / op (OPD EHF E!/ E+/ &) l) & (/ (E?EE9E) 3 F-)D %m= (HEOE9EE).6,- $ 6 / & %R ] (NEEV)./% SD # 612 % & / *^ (/ E 2 / \] ef &Y.-% (/ / % 612 # $ % & % 2 / /.b,/ HU & bqy %!+ 4=; r.- :,- # ; X- / %&, 6^ d sd block randomization 2 3,/ 6* S* E E.* Hb ?EOEVE?EE?O 3.-, =, r ELDL Ehols ETG E% = Eg / o-.-, =; j2d :2) & - )q2 % %! HUU a 3 1+K = a t: 3 3, / 6* 1+K = a > # 3 1+K = a >) UUUmg/d # 3 # 3 / D ()* (#- = a > (d",] sd a >) HUUmg.- / D ()* )D.- % % g&12 6) u3 bf- Ev3 $2 gw %&h[] %!k g&12 w/y &.- % %-%. 3?O2 V (HUUmg) w/y./% :! ;<! x. %=+p Z g+ / -% & - %&!k bc.6 2`- ar- # $ 6 / SR% + / (/ %d" -%& gky %d" bc 2 ef&= <, 4+/2 99H 2.6 %!",< D %/ 2, g3 (E?E8) % 6F- %f ) 4+/2. F < 7 %/ / *^!" ()* % & =2.6 / E- % # - (HEO) f <, ()* \] / -% ()* \].- % F < 99H % > E 3.6* i2, gh3,& 2 / )cf! )cj/! 3 5 %!K bf %;1 * 6Y ()* (UE9EVENEE8) +/, %2 3 /.-% (NEE8E?E) # $ 6 & /, g3 a: ()* (E9E?E).6,SR 6,/ D + 3!2k
3 "#$/ "*" 8#%, ! "#$ (Fisher s exact test: p= 1.0) %&' (# "#$ #( )* +,-./ (Non-paired t-test: p= 0.71) X D 4T2, S 8?. 6, =, (- =; Hb 1.% S, 4T2 O. QRS (/ > 3, =; D, FY % S Hb 1 X.-%&,S %:RS T2 2 O 1+K = 6]? E- =../ / y= /%2K.- % % 6) UU & d" = VU & - 6- %2] (/ - f - /%2K./% D (/ D ()* U f d" = OU./% ; = %&.- SD & #&2 dt2,s #q.-, & % & d" %!/ %F)* 6=* =;, p - 6 & >?> 6 2/ -#' t!r, ` s D :wilcaxon rank-sum TesTs, ) )< / U/UH &/ P Value.- % (ontingency-table )* # )< #&2.- %!2 6& < z.- % Spss 6^ d sd -, 4][p &,qd.* 2 3, %*:2 p = (2, &?H) & HU D 4:RS.- 7D 3?O 4,/ /.6, < O 2.? & & E E Es. E% z,!2 LDL E22!/ Hb 1, 3 H, 3 ) &.- 7D 6. 3.F g / =; ( 3 ZdY =; g!12 )q2 g+ F =..-
4 239 /...+#, -%.% /!" )*% (# ( #( 0 # #( &67 8./ P-value* U/V? U/?V U/? U/?U U/O8V U/VUV U/88U U/UN # $% U/8 98/N N/9 U/ O/? /O /H9 /VU V/H 9/H?U9/N??8/? V9/V??/N OH/O 8V/V 9/O8 U/?9 NU/UV N/V9!" O?U OHN OH 8? NN V?/V O/U V/U V?/U V V NN 9 8U 8U N/8 /V H?/H OO/U FS (mg/dl) S (4pM) (mg/dl) (Y) Hblc (g/dl) (#!/) N? /U N/V 8OU N9 (mg/dl)!2 /V N/O?VH 89/H?UN/H?U 8 (mg/dl) 22!/ V/9??H/? O8?N/8?H/? H NU LDL (mg/dl) 8H/ OO/??8? O? U? /,! "#$ %& ' ()*& +,-./ "526 ;: #9 05' P-value* U/UU U/NN U/UV U/UU U/??V U/N U/8U U/HVV *: Paired t-test # $% U/8 O/N N/9 H9/8 O/? O/9 /H9 /?N V/H N/NU?U9/N O/U V9/V VU/V OH/O 8V/V 9/O8 N/9 NU/UV N?/UV!" O?U?8H OH 8U NN V?/V U/ V/U VV/U V 9 NN U9 8U N/8 H/9 H?/H HO/U & VU VU VU VU VU FS (mg/dl) S (4pM) (mg/dl) (Y) Hblc (g/dl) (#!/) N? /U N/V 8OU N9 (mg/dl)!2 /N HH/V 88U NN VU 89/H?UN/H?U 8 (mg/dl) 22!/ 88/9?U/8?VH OV VU?N/8?H/? H NU LDL (mg/dl)?o/o?v/? VV 98 VU
5 "#9/ "*" 8#%, /,! "#$ %& ' ()*& +,-./ "526 7 P-value* U/UON U/8U U/UUUH U/9O8 U/UUUH U/?N U/?O9 U/U8 *: Paired t-test # $%!" & 98/N??8/? OHN V FS (mg/dl) H8/O 8/8?HV 9U VU U/ H/U /O O/N /VU /H??/N?8V/8 8V/V OV/? U/?9 U/8? 8? OH V V O/U 8/V 9 ON 8U?N /V /? VU VU VU S (4pM) (mg/dl) (Y) Hblc (g/dl) 9/H N/V9 V?/U OO/U (#!/) 9/ON NU/9N U,V OV/U VU /V VO/V V/9 OV/9 8H/ 8O/9 N/O 9O/8??H/??/9 OO/? 8?/O?VH OU O8 88O?8??? N O? O U? NH VU VU VU (mg/dl)!2 (mg/dl) 22!/ LDL (mg/dl) %9H) #!/ 8/UV 2,.(P=U/U?V) ()* / / D ()* (#!/ O/HV 2 /H cl 432 (P< U/UUUH) % S %=.(P=U/9) S %=, FG@ 86!@! 6 DEF =; &[D j2dk k G; V/N 22!/ 3,. S, (P=U/8)./ D (/ (/?V 2 cl %9H) mg/dl cl %9H) 8mg/dl 22!/ 2, Z[ (P=U/?O) / D (/ (N/8 2 }U/V 3, LDL S %= =; D,.(P=U/HV) S ()* ( 2 cl %9H) O mg/dl?u} (?O 2 cl %9H)? mg/dl LDL NO/U} 2,, Z[ (P=U/U)./ D (/ X ) 3,.+ %= ) LDL (/ (8N/H? 2 }U/?N cl %9H)?mg/dl!2.6* 2 D %N 3, Hb 1 G; X 2,, < 6 Hb 1 (/ X.6* (/, -.(P=U/O) + %=, 2 2:! : % 6* NPH? & #&2 NPH?,& & w/././%,3 ) Regular 6* 3 / %&.6* (/ (Y /V 2 /?O cl %9H) Y / / 2,/ 6*, FY./ D ()* (Y? 2 cl%9h) Y 9/8 =; D 2,.(P< U/UUUH) 3,/ 6*, ( %8N :!.- =; S MI, 8/8 2 U/? cl %9H) #!/ /V 3, %= T2 / / D ()* (#!/
6 233 /...+#, -%.% /!" )*% (# ( #( 5 <= >12 4 5&67./ 8 P-value* # $% # $% U/O8 NU/H }V/H??N/V }??/HH FS U/9 /NO 8O/N H?/UV V/98 S (4pM) <U/UUUH O/8?O/OH?N/HU }8/?H U/UUV??/U?/NN /U }O/9? Hb1c U/??? O/O O/NN H/UU?/V U/UV HH/8?/9U 8N/HN }H/UU!2 U/9V?O/O8 }?/?H?N/ /UV 22!/ U/U9H 9/8V }N/8 8U/NH N/9U LDL ) 3, Hb 1. QRS < %F&/ 3 % (</O%) <, G;.-% / + %& &/ (/ 2, Hb 1 T2 #] 7 4=; 6+ 3, Hb 1 h[] - =; / #] %- 2% =;,-,3 3 &/ < 7 g 2 % q w/y (HUUmg/dl).- =; Hb 1 &/ (/ %?O/H 2, 3, FY / D ()* (9/8u/d), S / % S (/ (/u/d) %8,& (/ -%, QRS < w 5i2, S 3, Hb 1 (/ %?H/V (/ > (8) F& D.-% 3 $ 6 & (U) F& [.,/ l) 3 )* (/ 22 (?) Eviles, Sant, Raskin, Sinding 3 )* %?O %?H ~ /./ l) Type 2 6 & +,& ()*.-% =; q S & =; ()*.6 `- /,& / & (N),/ 6* 6* (?E?H) troglitazone (?OE?8), g3.6,- l) /%!2 2, FY (P=U/N), Z[ (P=U/?N). S ()* 8mg/dl.(P=U/UV) - %= >) H* ), F & F.2 F&, %&!k ) 0 % - %7 3,/ Z: & 8 2.S %R, 2 3/ 3 / %/-./ g&12 I F!&] 3 5i2 =; & 6+ %;1 6Y (?EUE9ENEE) # $ 6 (?) > $ 6 # $ 6 & 3 5i2. #!= 3 /.6, 2QRS 3 / %!+ 412 =;.6./% i2 QRS + 3,/ 6*, / (/ K /H 3,/ 6*,.6 - T2 2, FY. S Hb 1 %!+ 4=; &/ (/.S, %:RS &/ %N Hb 1 3,. (?EU) % z e[ / (/ / 2,
7 "#>/ "*" 8#%, Hb 1 (/ \] 3 / *^, ( %N/ V / 6+ &/ ()* &/ %8N.- gky 2, #!/ /V 3, =; & % S ()* #!/ 8 2 /, S &/ ()*,/ 6*.+ QRS z T2 1. Dagogo-lack S, santiago jv. Pathophysiology of type 2 diabetes and modes of action of therapeutic interventions. rth Intern med 1997; 157: Melander. oral antidiabetic drugs an overview. Diabetes med 1996; 13(9 suppl 6): s Scheen. Drug treatment of non-insulin dependent diabetes mellitus in the 1990 chievements and future developments. Durgs. 1997, 54: braira, owell, Nuttal FQ, Nagel N, onstock P, etal. Veteran affairs ooperative Study on glycemic control and complication in Type II diabetes (V SDM). Results of the feasibility trail. Veterans ffairs cooperative study in Type 2 diabetes. Diabetic care. 1995; 18: Herny RR, Gumbiner, Dizeler T, wallace P. lyon R, Gluaber HS Intensive onventional insulin therapy for type2 diabetes. Metabolic effects during a 6 mo outpatient Trail. Diabetes care. 1993; 16: ailey. Turner R. Metformin N Engl med: 1996; 334; Sirtory RS, pasik. Re-evaluation of a biguanide, metfomin. Mechanism of action and tolerability. Pharmacol Res 1994, 334; Davidson M, Peters L. n overview of metformin in the treatment of type 2 diabetes mellitus. m med 1997: Grarber, Duncon TG, Goodman M, mills D, Rohlt L. Double blind, placebo- ontrolled, dose-response trail. m of med 1997:102:494-7 in glycamic control and reduction of metabolic risk factors. Eur clin phrmacol. 1993; 44: Giugliiano D.Quatraro, cosol: G, minei, ceriello et al. metformin for obese, insulintreated diabetic patients. 11. Defronzo R, Goodman M. Efficacy of metformin in patients with non-insulin dependent diabetes mellitus. The Multicenter metformin Study Group. N Engle med: 1995, 333: Lefebure P, scheen. Improving the action of insulin. lin invest med. 1995; 18: b Pagano G, Tagliaferro V, carata Q, aselle MT, ozzoc, uitellif, et al. Metformin reduces requirements in type 1 (insulin-dependent)diabetes. Diabetologia 1983; 24:
8 23: /...+#, -%.% / 14. Defronzo R, arzilai N, Simonson D. Mechanism of metformin action in obese and lean non insulin-dependent diabetic subject. Sclin Endocrinol metab. 1991; 73: United Kingdom Prospective Diabetes Study 24:6-year, randomized, control trail comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed Type2 diabetes that could not be controlled with diet Therapy. United Kingdom Prospective Diabetes study grou. nn intern med. 1998; 128: Scheen, letiexhe MR, Letebure P. Effects of metformin in obese patients with impaired glucose tolerance. Diabetes Metab Rev. 1995; 11: Effect of intensive blood-glucose control with metformin on complications in overweight patients ith Type2 diabetes (UKPDS). UK prospective Diabetes Study (UKPDS) GROUP. Lancet: 1998; 325: Laissa viles-santa, MD; oyce sinding, MSN, RN; and philip Raskin, MD. nn Intern Med. 1999; 131: ergenstal R, ohnson M, whipple D, Nolle D, oycek, Roth L, et al. dvantages of adding metformin to multiple dose in insulin therapy in type 2 diabetes.!" )*% 20. Gigliano Quatraro, onsoli G, Minei, eriello, De Rosa N, etal Metformin for obese insulin treated diabetic Patients; improvement in glycemic control and reduction of metabolic risk factors, Eur ckin Pharmacol. 193; 44: viles-sant, sinding, Raskin P. The effects of metformin in poorly controlled insulin-treated type 2 diabetes mellitus. [bstract]. Diabetes. 1998; 47(suppl(1): International Diabetes Federation ongress, November 5-10, 2000, Mexico city, Mexico. 23. ahnson L. Wolf sl, kababi um. Efficacy ot insulin and suftonglurea combination therapy in Type 2 diabetes. meta-analysis of randomized placebo-ontrolled trials. rch Inten Med. 1996; 156: Halimi S, corticelli P,enhamou PY. ombination of insulin and snlfonyfureas. literature review. m Med Dogogo-ack S,Santiago V. Pathopysiology of type 2 diabetes and modes of action of therapeutic interventions. rch Intern Med. 1997; 157: Saltil R, Olefski M. Thiazolidinediones in the treatment of insulin resistance and type 2 diabetes. Diabetes 1996; 45:
Type II diabetes: How to use the new oral medications
Type II diabetes: How to use the new oral medications A TWO-PART INTERVIEW WITH NANCY J.V. BOHANNON, MD, BY DAVID B. JACK, MD Several new oral drugs have been approved for the management of type II diabetes.
More informationInsulin Algorithm for Type 2 Diabetes Mellitus in Children and Adults
Insulin Algorithm for Type 2 Diabetes Mellitus in Children and Adults Stock # 45-11647 Revised 10/28/10 Glycemic Goals 1,2 Individualize goal based on patient risk factors A1c 6%
More informationUsing a Flow Sheet to Improve Performance in Treatment of Elderly Patients With Type 2 Diabetes
Special Series: AAFP Award-winning Research Papers Vol. 31, No. 5 331 Using a Flow Sheet to Improve Performance in Treatment of Elderly Patients With Type 2 Diabetes Gary Ruoff, MD; Lynn S. Gray, MD, MPH
More informationJill Malcolm, Karen Moir
Evaluation of Fife- DICE: Type 2 diabetes insulin conversion Article points 1. Fife-DICE is an insulin conversion group education programme. 2. People with greater than 7.5% on maximum oral therapy are
More informationINSULIN ALGORITHM FOR TYPE 2 DIABETES MELLITUS IN CHILDREN 1 AND ADULTS
Publication # 45-11647 Targets*
More informationGuidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center
More informationIMPROVED METABOLIC CONTROL WITH A FAVORABLE WEIGHT PROFILE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH INSULIN GLARGINE (LANTUS ) IN CLINICAL
464 IMPROVED METABOLIC CONTROL WITH A FAVORABLE WEIGHT PROFILE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH INSULIN GLARGINE (LANTUS ) IN CLINICAL PRACTICE STEPHAN A SCHREIBER AND ANIKA RUßMAN ABSTRACT
More information嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯
The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized
More informationStrengthening the Pharmacist Skills in Managing Diabetes Practice Based Program 27 Contact Hours
Strengthening the Pharmacist Skills in Managing Diabetes Practice Based Program 27 Contact Hours Presented by New York State Council of Health system Pharmacists October 18 19, 2013 St. John s University,
More informationNovel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety
Novel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety Anders Svensson MD, PhD Head of Global Clinical Development Metabolism, F Hoffmann LaRoche Ltd. Basel, Switzerland Overview of
More informationDiabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus
Melissa Meredith M.D. Diabetes mellitus is a group of metabolic diseases characterized by high blood glucose resulting from defects in insulin secretion, insulin action, or both Diabetes is a chronic,
More informationBritni Hebert, MD PGY-1
Britni Hebert, MD PGY-1 Importance of Diabetes treatment Types of treatment Comparison of treatment/article Review Summary Example cases 1 out of 13 Americans have diabetes Complications include blindness,
More informationű Ű ű ű ű űű ű ő ő ű ű ő ő ő Ű ű ő ő Ű ő ű ű ő ű ű Ű ű Ő ű ű Ő Ű ű ű Ű Ű ő ű Ű ű ű ű Ű Ű Ű ő ő ű ő ű Ű Ő ő ő Ő ő ű ő ő Ő ű Ű ű ő Ű Ő ű ő ő ű Ő Ű ű ő ő ő Ő Ű Ő ű ő ű ű Ű Ű ű Ű ű Ű ű Ű Ű ű ű ű Ő ŰŐ ő Ű ő
More informationCME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus
CME Test for AMDA Clinical Practice Guideline Diabetes Mellitus Part I: 1. Which one of the following statements about type 2 diabetes is not accurate? a. Diabetics are at increased risk of experiencing
More informationPersonalized Therapy Algorithms for Type 2 Diabetes: A Phenotypization-based Approach
Personalized Therapy Algorithms for Type 2 Diabetes: A Phenotypization-based Approach Riccardo Candido on behalf of the Personalized Therapy AMD Study Group Diabetes Canter A.S.S. 1 Triestina, Italy BACKGROUND
More informationtrends in the treatment of Diabetes type 2 - New classes of antidiabetic drugs. IAIM, 2015; 2(4): 223-
Review Article Pharmacological trends in the treatment of Diabetes type 2 - New classes of antidiabetic Silvia Mihailova 1*, Antoaneta Tsvetkova 1, Anna Todorova 2 1 Assistant Pharmacist, Education and
More informationInsulin degludec (Tresiba) for the Management of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks
Background: Insulin degludec (Tresiba) for the Management of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks Final Background and Scope November 19, 2015 The Centers for Disease Control
More informationCASE B1. Newly Diagnosed T2DM in Patient with Prior MI
Newly Diagnosed T2DM in Patient with Prior MI 1 Our case involves a gentleman with acute myocardial infarction who is newly discovered to have type 2 diabetes. 2 One question is whether anti-hyperglycemic
More informationINSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT?
INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT? MARTHA M. BRINSKO, MSN, ANP-BC CHARLOTTE COMMUNITY HEALTH CLINIC CHARLOTTE, NC Diagnosed and undiagnosed diabetes in the United
More informationTYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.
TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION Robert Dobbins, M.D. Ph.D. Learning Objectives Recognize current trends in the prevalence of type 2 diabetes. Learn differences between type 1 and type
More informationType 2 Diabetes Mellitus and Insulin resistance syndrome in Children
Type 2 Diabetes Mellitus and Insulin resistance syndrome in Children Anil R Kumar MD Pediatric Endocrinology MCV/VCU, Richmond VA Introduction Type 2 diabetes mellitus (T2 DM) has increased in children
More informationGlobal Guideline for Type 2 Diabetes
INTERNATIONAL DIABETES FEDERATION, 2005 Clinical Guidelines Task Force Global Guideline for Type 2 Diabetes Chapter 10: Glucose control: insulin therapy Copyright All rights reserved. No part of this publication
More information3 WORKSHOP CONGIUNTO SICOb SID SIO 7 MARZO 2014 L integrazione tra terapia medica e chirurgica nel trattamento del paziente obeso diabetico
3 WORKSHOP CONGIUNTO SICOb SID SIO 7 MARZO 2014 L integrazione tra terapia medica e chirurgica nel trattamento del paziente obeso diabetico Recidive del diabete dopo terapia chirurgica La quantificazione
More informationDiagnosis, classification and prevention of diabetes
Diagnosis, classification and prevention of diabetes Section 1 1 of 4 Curriculum Module II 1 Diagnosis, classification and presentation of diabetes Slide 2 of 48 Polyurea Definition of diabetes Slide 3
More informationThe Natural History of Type 2 Diabetes: Practical Points to Consider in Developing Prevention and Treatment Strategies
CLINICAL DIABETES VOL. 18 NO. 2 Spring 2000 PRACTICAL POINTERS The Natural History of Type 2 Diabetes: Practical Points to Consider in Developing Prevention and Treatment Strategies Barbara A. Ramlo-Halsted,
More informationGUIDELINES FOR THE TREATMENT OF DIABETIC NEPHROPATHY*
71 GUIDELINES FOR THE TREATMENT OF DIABETIC NEPHROPATHY* Ryuichi KIKKAWA** Asian Med. J. 44(2): 71 75, 2001 Abstract: Diabetic nephropathy is the most devastating complication of diabetes and is now the
More informationDiabetes Complications
Managing Diabetes: It s s Not Easy But It s s Worth It Presenter Disclosures W. Lee Ball, Jr., OD, FAAO (1) The following personal financial relationships with commercial interests relevant to this presentation
More informationSHORT CLINICAL GUIDELINE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SHORT CLINICAL GUIDELINE SCOPE 1 Guideline title Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes 1.1 Short title Type 2
More informationUse of Glimepiride and Insulin Sensitizers in the Treatment of Type 2 Diabetes A Study in Indians
Original Article Use of Glimepiride and Insulin Sensitizers in the Treatment of Type 2 Diabetes A Study in Indians A Ramachandran, C Snehalatha, J Salini, V Vijay Abstract Aim : Short-term efficacy of
More informationInsulin or GLP1 How to make this choice in Practice. Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust
Insulin or GLP1 How to make this choice in Practice Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust Workshop Over View Considerations/barriers to treatments in type 2
More informationHEALTH SERVICES POLICY & PROCEDURE MANUAL
Page 1 of 5 PURPOSE To assure that DOP inmates with Diabetes, who require insulin therapy, are receiving high quality Primary Care for their condition. POLICY All DOP Primary Care Providers are to follow
More informationDiabetes is a. A case for prevention of type 2 diabetes mellitus
A case for prevention of type 2 diabetes mellitus Joseph Cook, DO Diabetes is a disease that has reached epidemic proportions in the United States and around the world. This is troubling because, as bad
More informationDouble Diabetes: Definition, Diagnosis, Treatment, Prediction and Prevention.
Double Diabetes: Definition, Diagnosis, Treatment, Prediction and Prevention. Professor Paolo Pozzilli University Campus Bio-Medico, Rome Institute of Cell & Molecular Science, Queen Mary, University of
More informationTreating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group. Learning Objectives. Background. CAPA 2015 Annual Conference
Treating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group Learning Objectives To accurately make the diagnosis of pre-diabetes/metabolic syndrome To understand the prevalence
More informationSevere Hypoglycemia in Type 2 Diabetes. A Hospital-based Retrospective Study
2006 17 73-77 Severe Hypoglycemia in Type 2 Diabetes A Hospital-based Retrospective Study Ya-Chun Hsiao, and Ming-Nan Chien 1 Division of Endocrinology and Metabolism, Department of Internal Medicine Mackay
More informationWhich drugs should be used to treat diabetes in cirrhotic patients?
Which drugs should be used to treat diabetes in cirrhotic patients? Frankfurt am Main 10-12 September 2015 Jörg Bojunga Medizinische Klinik I Johann Wolfgang Goethe-Universität Frankfurt am Main Significance
More informationSection 5: Type 2 Diabetes
SECTION OVERVIEW Definition and Symptoms Blood Glucose Monitoring Healthy Eating Physical Activity Oral Medication Insulin Sharps Disposal Definition and Symptoms Type 2 diabetes is occurring more frequently
More informationSubcutaneous Infusion of GLP-1 for 7 Days Improves Glycemic Control Over a Broad Dose Range in Patients with Type 2 Diabetes
Subcutaneous Infusion of GLP-1 for 7 Days Improves Glycemic Control Over a Broad Dose Range in Patients with Type 2 Diabetes Mario R. Ehlers, 1,2 Roderick E. Harley, 1 Annette L. Mathisen, 1 Roberta Schneider,
More informationFactors Affecting Use of Insulin Pens by Patients With Type 2 Diabetes
Clinical Care/Education/Nutrition/Psychosocial Research Original Research Factors Affecting Use of Insulin Pens by Patients With Type 2 Diabetes Richard R. Rubin, PHD 1,2 and Mark Peyrot, PHD 1,3 1 Department
More informationTake a moment Confer with your neighbour And try to solve the following word picture puzzle slides.
Take a moment Confer with your neighbour And try to solve the following word picture puzzle slides. Example: = Head Over Heels Take a moment Confer with your neighbour And try to solve the following word
More informationUtilization of Oral Hypoglycemic Agents in a Drug-Insured U.S. Population
Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E Utilization of Oral Hypoglycemic Agents in a Drug-Insured U.S. Population STEPHEN J. BOCCUZZI, PHD 1 JENIFER WOGEN, MS 1
More informationType 2 diabetes is a progressive. status
Type 2 diabetes is a progressive disease: its treatment the current status Associate Professor Jonathan Shaw Why is type 2 diabetes so hard to treat? How to choose the right glucose-lowering g drug? Page
More informationTREATMENT OF TYPE 2 DIABETES
- 1 - Submitted to Acta Clinica Belgica TREATMENT OF TYPE 2 DIABETES André J. Scheen Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman, Liège, Belgium. Address
More informationCardiovascular Effects of Drugs to Treat Diabetes
Cardiovascular Effects of Drugs to Treat Diabetes Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical companies Clinical Trials:
More informationDiabetes Mellitus 1. Chapter 43. Diabetes Mellitus, Self-Assessment Questions
Diabetes Mellitus 1 Chapter 43. Diabetes Mellitus, Self-Assessment Questions 1. A 46-year-old man presents for his annual physical. He states that he has been going to the bathroom more frequently than
More informationA prospective study on drug utilization pattern of anti-diabetic drugs in rural areas of Islampur, India
Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2015, 7 (5):33-37 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4
More informationAlgorithms for Glycemic Management of Type 2 Diabetes
KENTUCKY DIABETES NETWORK, INC. Algorithms for Glycemic Management of Type 2 Diabetes The Diabetes Care Algorithms for Type 2 Diabetes included within this document are taken from the American Association
More informationThe Arguments: T2DM - tremendous economic burden globally Lifestyle / Pharm Rx:
James Cromie The Arguments: T2DM - tremendous economic burden globally Lifestyle / Pharm Rx: INEFFECTIVE and UNSUSTAINED Bariatric surgery is an Effective and Durable treatment option Well established
More informationPractical Applications of Insulin Pump Therapy in Type 2 Diabetes
Practical Applications of Insulin Pump Therapy in Type 2 Diabetes Wendy Lane, MD For a CME/CEU version of this article please go to www.namcp.org/cmeonline.htm, and then click the activity title. Summary
More informationSecondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence
Guidelines Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence Stroke/TIA Nearly 700,000 ischemic strokes and 240,000 TIAs every year in the United States Currently, the risk for
More informationHow To Prevent Type 2 Diabetes
Introduction The Primary Prevention of Type 2 Diabetes AADE Practice Synopsis Issued December 1, 2014 The prevalence of type 2 diabetes is reaching epidemic proportions with more than 9.3% of adults in
More informationINSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT
INSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT APIRADEE SRIWIJITKAMOL DIVISION OF ENDOCRINOLOGY AND METABOLISM DEPARTMENT OF MEDICINE FACULTY OF MEDICINE SIRIRAJ HOSPITOL QUESTION 1 1. ท านเคยเป นแพทย
More informationInterventions for improving glycemic control in type 2 diabetic patients
Interventions for improving glycemic control in type 2 diabetic patients Evgenia Vlachou 1, Zambia Vardaki 2, Urania Govina 1, Anna Kavga-Paltoglou 3, Vassiliki Kutsopoulou-Sofikiti 1, Martha Kelesi-Stavropoulou
More informationCardiovascular Disease in Diabetes
Cardiovascular Disease in Diabetes Where Do We Stand in 2012? David M. Kendall, MD Distinguished Medical Fellow Lilly Diabetes Associate Professor of Medicine University of MInnesota Disclosure - Duality
More informationTreating dual defects in diabetes: Insulin resistance and insulin secretion
Treating dual defects in diabetes: Insulin resistance and insulin secretion Nancy J.V. Bohannon, MD Am J Health-Syst Pharm. 2002; 59(Suppl 9):S9-13 ABSTRACT: The therapeutic goals in patients with type
More informationRobert Okwemba, BSPHS, Pharm.D. 2015 Philadelphia College of Pharmacy
Robert Okwemba, BSPHS, Pharm.D. 2015 Philadelphia College of Pharmacy Judith Long, MD,RWJCS Perelman School of Medicine Philadelphia Veteran Affairs Medical Center Background Objective Overview Methods
More informationEFFICACY OF PIOGLITAZONE AS AN ADD ON DRUG WITH INSULIN, GLIBENCLAMIDE AND METFORMIN IN PATIENTS WITH UNCONTROLLED TYPE 2 DIABETES MELLITUS
Diabetes Clinic and Research Centre, Shreeniwas, Opposite Dhantoli Park, Nagpur, 440 012 India Phone: + 91 712 521898 Fax: + 91 712 54 59 89 E-mail: sharad@nagpur.dot.net.in Professional Paper EFFICACY
More informationPathophysiology of Type 2 Diabetes and Its Treatment Policy
Research and Reviews Pathophysiology of Type 2 Diabetes and Its Treatment Policy JMAJ 53(1): 41 46, 2010 Kohei KAKU* 1 Abstract Impaired insulin secretion and increased insulin resistance, the main pathophysiological
More informationHow To Determine The Prevalence Of Microalbuminuria
Research Journal of Pharmaceutical, Biological and Chemical Sciences Prevalence of Microalbuminuria in relation to HbA1c among known Type2 Diabetic Patients in Puducherry population Muraliswaran P 1 *,
More informationInsulin Analogues versus Pump Therapy in Type 2 Diabetes: Benefits from Pump Therapy
Insulin Analogues versus Pump Therapy in Type 2 Diabetes: Benefits from Pump Therapy Eric RENARD, MD, PhD Endocrinology Dept, Lapeyronie Hospital Montpellier, France e-renard@chu-montpellier.fr Type 2
More informationThe Economic Impact and Cost-Effectiveness of Glucose Monitoring
The Economic Impact and Cost-Effectiveness of Glucose Monitoring William H. Herman, MD, MPH Stefan S. Fajans/GlaxoSmithKline Professor of Diabetes Professor of Internal Medicine and Epidemiology University
More informationNancy S. Swayze. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume V, 2000-2001. A. Background
Efficacy Of Insulin Sensitizing Agents In Subjects With Metabolic Syndrome X And Impaired Glucose Tolerance After 6 Months Of Diet And Exercise Therapy Nancy S. Swayze A. Background Impaired glucose tolerance
More informationNONINSULIN-DEPENDENT diabetes mellitus
0021-972X/97/$03.00/0 Vol. 82, No. 8 Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright 1997 by The Endocrine Society An Overnight Insulin Infusion Algorithm Provides Morning
More informationMy Doctor Says I Need to Take Diabetes Pills and Insulin... What Do I Do Now? BD Getting Started. Combination Therapy
My Doctor Says I Need to Take Diabetes Pills and Insulin... What Do I Do Now? BD Getting Started Combination Therapy How Can Combination Therapy Help My Type 2 Diabetes? When you have type 2 diabetes,
More informationEvaluation of Dosing and Clinical Outcomes in Patients Undergoing Conversion of Insulin Glargine to Insulin Detemir
Evaluation of Dosing and Clinical Outcomes in Patients Undergoing Conversion of Glargine to Detemir Ginelle A. Bryant, Pharm.D., Deanna L. McDanel, Pharm.D., Kathleen E. Horner, Pharm.D., Karen B. Farris,
More informationIntroduction. Yi-Chun Lin 1,2, Liang-Yu Lin 1,3, Huei-Fang Wang 4, Hong-Da Lin 1,2 *
ORIGINAL ARTICLE Fasting Plasma Lactate Concentrations in Ambulatory Elderly Patients With Type 2 Diabetes Receiving Metformin Therapy: A Retrospective Cross-sectional Study Yi-Chun Lin 1,2, Liang-Yu Lin
More informationThe basal plus strategy. Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE
The basal plus strategy Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE ADA/EASD guidelines recommend use of basal insulin as early as the second step
More informationPATHWAYS TO TYPE 2 DIABETES. Vera Tsenkova, PhD Assistant Scientist Institute on Aging University of Wisconsin-Madison
PATHWAYS TO TYPE 2 DIABETES Vera Tsenkova, PhD Assistant Scientist Institute on Aging University of Wisconsin-Madison Overview Diabetes 101 How does diabetes work Types of diabetes Diabetes in numbers
More informationAttitude towards Insulin Therapy among Patients with Type 2 Diabetes in Tripoli, Libya
Ibnosina J Med BS 127 ARTICLE Attitude towards Insulin Therapy among Patients with Type 2 Diabetes in Tripoli, Libya Laila T. Sabei and Mohamed H. Sammud Department of Community and Family Medicine, Faculty
More informationCASE A1 Hypoglycemia in an Elderly T2DM Patient with Heart Failure
Hypoglycemia in an Elderly T2DM Patient with Heart Failure 1 I would like to introduce you to Sophie, an elderly patient with long-standing type 2 diabetes, who has a history of heart failure, a common
More informationADJUSTING INSULIN DOSES CONFLICTS OF INTEREST
ADJUSTING INSULIN DOSES CONFLICTS OF INTEREST Vahid Mahabadi, MD Research grants from Sanofi and Amylin Pharmaceutical Companies Mayer B. Davidson, MD Advisory Board Sanofi Pharmaceutical Company Chief
More informationInsulin: Breaking Barriers Enhancing Therapies. Jerry Meece, RPh, FACA, CDE jmeece12@cooke.net
Insulin: Breaking Barriers Enhancing Therapies Jerry Meece, RPh, FACA, CDE jmeece12@cooke.net Questions To Address Who are candidates for insulin? When do we start insulin? How do the different types of
More informationType 2 Diabetes Adult Outpatient Insulin Guidelines Sutter Medical Foundation. February 2011.
Type 2 Diabetes Adult Outpatient Insulin Guidelines. GENERAL RECOMMENDATIONS Start insulin if A1C and glucose levels are above goal despite optimal use of other diabetes medications. (Consider insulin
More informationThe U.K. Prospective Diabetes Study
Clinical Care/Education/Nutrition O R I G I N A L A R T I C L E Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Comparison of two treatment algorithms using insulin glargine
More informationMEDICAL POLICY POLICY TITLE DIABETIC SELF-MANAGEMENT TRAINING PROGRAM POLICY NUMBER MP- 2.076
Original Issue Date (Created): July 1, 2005 Most Recent Review Date (Revised): Effective Date: May 24, 2011 August 31, 2011- RETIRED I. POLICY Initial diabetic self-management training (DSMT) may be considered
More informationA Prospective Evaluation of Insulin Dosing Recommendations in Patients with Type 1 Diabetes at Near Normal Glucose Control: Bolus Dosing
Journal of Diabetes Science and Technology Volume 1, Issue 1, January 2007 Diabetes Technology Society ORIGINAL ARTICLES A Prospective Evaluation of Insulin Dosing Recommendations in Patients Allen B.,
More informationComparative Review of Oral Hypoglycemic Agents in Adults
SECTION 18.5 Comparative Review of Oral Hypoglycemic Agents in Adults Harinder Chahal For WHO Secretariat Table of Contents Acronyms:... 3 I. Background and Rationale for the review:... 4 II. Medications
More informationInsulin Therapy In Type 2 DM. Sources of support. Agenda. Michael Fischer, M.D., M.S. The underuse of insulin Insulin definition and types
Insulin Therapy In Type 2 DM Michael Fischer, M.D., M.S. Sources of support NaRCAD is supported by a grant from the Agency for Healthcare Research and Quality My current research projects are funded by
More informationGlucose Management University of Colorado Hospital
Glucose Management University of Colorado Hospital Bridget Everhart, MSN, NP, CDE Inpatient Diabetes Educator Bridget.Everhart@uch.edu M F Pager 303 266-7898 UCH Diabetes Program Michael McDermott MD Diabetes
More informationfrom 5 September 2013
Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII - Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in
More informationEffect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE - Diabetes
Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE - Diabetes This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim
More informationTYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY. Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU
TYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU Objectives: 1. To discuss epidemiology and presentation
More informationType 2 Diabetes - Pros and Cons of Insulin Administration
Do we need alternative routes of insulin administration (inhaled insulin) in Type 2 diabetes? Cons: Suad Efendic Karolinska Institutet, Sweden The Diabetes Management Situation Today Diabetes is a growing
More information6.4 Diabetes. 6 Priority diseases and reasons for inclusion. Background. Developments since 2004. See Background Paper 6.4 (BP6_4DM.
6 Priority diseases and reasons for inclusion 6.4 Diabetes See Background Paper 6.4 (BP6_4DM.pdf) Background Diabetes and diabetes-related illnesses place an enormous burden on the health care systems
More informationLinköping University Post Print
Linköping University Post Print Can diabetes medication be reduced in elderly patients?: An observational study of diabetes drug withdrawal in nursing home patients with tight glycaemic control Peter Sjöblom,
More informationGestational Diabetes Screening and Treatment Guideline
Gestational Diabetes Screening and Treatment Guideline Major Changes as of October 2015... 2 Screening Recommendations and Tests... 2 Diagnosis... 2 Treatment Goals... 3 Lifestyle modifications/non-pharmacologic
More informationPlasma glucose and insulin responses to mixed meals: Impaired fasting glucose re-visited
421036DVR8410.1177/1479164111421036Bhat et al.diabetes and Vascular Disease Research Orginal Article Plasma glucose and insulin responses to mixed meals: Impaired fasting glucose re-visited Diabetes &
More informationDiabetes Medications: Insulin Therapy
Diabetes Medications: Insulin Therapy Courtesy Univ Texas San Antonio Eric L. Johnson, M.D. Department of Family and Community Medicine Diabetes and Insulin Type 1 Diabetes Autoimmune destruction of beta
More informationOverview and update of modern type 2 Diabetes philosophy and management. Dr Steve Stanaway Consultant Endocrinologist BCU
Overview and update of modern type 2 Diabetes philosophy and management Dr Steve Stanaway Consultant Endocrinologist BCU Diabetes economics 2009: 2.6M adults with DM in UK (90% type 2) 2025: est. > 4M
More informationPioglitazone in Combination with Insulin An Overview of Results from PROactive. Bernard Charbonnel, MD
Diabetes Management Pioglitazone in Combination with Insulin An Overview of Results from PROactive Bernard Charbonnel, MD Professor of Endocrinology and Metabolic Diseases, University of Nantes and Department
More informationIntensive Insulin Therapy in Diabetes Management
Intensive Insulin Therapy in Diabetes Management Lillian F. Lien, MD Medical Director, Duke Inpatient Diabetes Management Assistant Professor of Medicine Division of Endocrinology, Metabolism, & Nutrition
More informationIntensifying insulin therapy in patients with type 2 diabetes mellitus
The American Journal of Medicine (2005) Vol 118 (5A), 21S 26S Intensifying insulin therapy in patients with type 2 diabetes mellitus Irl B. Hirsch, MD From the Diabetes Care Center, Division of Endocrinology,
More informationEFFICACY OF BARIATRIC SURGERY IN OBESE INDIAN WITH TYPE 2 DIABETES MELLITUS
EFFICACY OF BARIATRIC SURGERY IN OBESE INDIAN WITH TYPE 2 DIABETES MELLITUS Subodh Banzal, Abhishek Singhai, Mohit Bhandari, Padmnabh Sharma, Rajesh Kumar Jha, Piyush Manoria 1. Associate Professor, DM,
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PC - Apidra, Levemir Therapeutic Class: Hormones and Synthetic Substitutes Therapeutic Sub-Class: Antidiabetic Agents Client: CA, CO, NV, OK, OR, WA and AZ Approval
More informationPrimary prevention of chronic kidney disease: managing diabetes mellitus to reduce the risk of progression to CKD
Primary prevention of chronic kidney disease: managing diabetes mellitus to reduce the risk of progression to CKD Date written: July 2012 Author: Kate Wiggins, Graeme Turner, David Johnson GUIDELINES We
More informationSponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,
More informationASSOCIATED FACTORS OF EJECTION FRACTION IN INSULIN-TREATED PATIENTS WITH TYPE 2 DIABETES
Rev. Med. Chir. Soc. Med. Nat., Iaşi 204 vol. 8, no. 4 INTERNAL MEDICINE - PEDIATRICS ORIGINAL PAPERS ASSOCIATED FACTORS OF EJECTION FRACTION IN INSULIN-TREATED PATIENTS WITH TYPE 2 DIABETES Gina Botnariu
More informationNone of the authors has a financial interest in any of the products discussed in this report.
The DEcIDE (Developing Evidence to Inform Decisions about Effectiveness) network is part of AHRQ's Effective Health Care Program. It is a collaborative network of research centers that support the rapid
More informationBASAL BOLUS INSULIN FOR MEDICAL- SURGICAL INPATIENTS
BASAL BOLUS INSULIN FOR MEDICAL- SURGICAL INPATIENTS C O N T A C T D I A B E T E S S E R V I C E S F O R M O R E I N F O R M A T I O N 8 4 7-9 1 7-6 9 0 7 THIS SLIDE PRESENTATION WAS PREPARED BY SUE DROGOS,
More informationInsulin myths and facts
london medicines evaluation network Insulin myths and facts Statement 1 Insulin is the last resort for patients with Type 2 diabetes After initial metformin and sulfonylurea therapy, NICE and SIGN suggest
More information